Clinical trial
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer
NCT03317119 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 11, 2018
- Completion date
- July 14, 2023
- Enrollment
- 26 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic colon carcinoma, metastatic colorectal carcinoma, metastatic rectal carcinoma, ras family gene mutation, stage iii colon cancer ajcc v7, stage iii colorectal cancer ajcc v7, stage iii rectal cancer ajcc v7, stage iiia colon cancer ajcc v7, stage iiia colorectal cancer ajcc v7, stage iiia rectal cancer ajcc v7, stage iiib colon cancer ajcc v7, stage iiib colorectal cancer ajcc v7, stage iiib rectal cancer ajcc v7, stage iiic colon cancer ajcc v7, stage iiic colorectal cancer ajcc v7, stage iiic rectal cancer ajcc v7, stage iv colon cancer ajcc v7, stage iv colorectal cancer ajcc v7, stage iv rectal cancer ajcc v7, stage iva colon cancer ajcc v7, stage iva colorectal cancer ajcc v7, stage iva rectal cancer ajcc v7, stage ivb colon cancer ajcc v7, stage ivb colorectal cancer ajcc v7, stage ivb rectal cancer ajcc v7